IBIO Stock — iBio, Inc.

iBio, Inc. (IBIO)

Updated October 16, 2026.

IBIO is a Stock. Total return is -100.0% over the past 18.2 years, 837.6 points behind SPY at 737.6%.

IBIO is a healthcare equity stock that trades as a single security rather than functioning as a traditional diversified ETF. With no reported distribution rate, expense ratio, or assets under management, this holding does not generate regular dividend income and lacks the transparency typical of actively managed or indexed dividend funds. It may appeal to investors seeking direct exposure to biotech or healthcare companies, though it does not serve as an income-generating vehicle for dividend-focused portfolios.

IBIO performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 18.2 years, 837.6 points behind SPY at 737.6%. Over the past year its total return — price change plus distributions reinvested — is -9.8%. Its deepest 1-year drawdown was 75.0%.

IBIO key facts

Asset type

Stock

Asset class

Equity

Inception date

08/19/2008

Distribution frequency

None

Last close

$0.77 (as of 2026-10-16)

Market cap

$38,252,492

Average volume

310000.0

Payment date

06/11/2018

Beta

1.257

Payout ratio

0.0%

EPS

$-0.32

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IBIO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 75.0%.

Who may consider IBIO — and who may not

It is a weaker fit for investors who need monthly cash flow (IBIO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IBIO

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions